Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of “Hold” from Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has been assigned a consensus recommendation of “Hold” from the ten analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $21.8571.

A number of analysts recently commented on the stock. Zacks Research cut shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Wall Street Zen lowered Keros Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. TD Cowen upgraded Keros Therapeutics to a “hold” rating in a research report on Friday, December 19th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th.

Hedge Funds Weigh In On Keros Therapeutics

A number of large investors have recently modified their holdings of KROS. Financial Management Professionals Inc. bought a new position in shares of Keros Therapeutics in the fourth quarter worth $29,000. Caitong International Asset Management Co. Ltd raised its position in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after buying an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after buying an additional 1,888 shares during the period. Farther Finance Advisors LLC purchased a new position in Keros Therapeutics during the third quarter worth about $47,000. Finally, SG Americas Securities LLC purchased a new position in Keros Therapeutics during the third quarter worth about $103,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Stock Performance

Shares of KROS opened at $10.99 on Friday. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $22.55. The business has a 50-day moving average of $16.68 and a 200 day moving average of $16.94. The firm has a market cap of $334.87 million, a P/E ratio of 6.04 and a beta of 0.87.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.37). The business had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $3.66 million. Keros Therapeutics had a net margin of 35.65% and a return on equity of 14.25%. Keros Therapeutics’s revenue for the quarter was down 87.2% compared to the same quarter last year. During the same period last year, the company earned ($1.14) earnings per share. As a group, research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.